Regeneron may be less effective against the omicron strain




The American company Regeneron announced today that its drug against kovid 19 could be less effective against homicron strains.


Source: Tanjug

Photo: Shutterstock / TAM99PH

Photo: Shutterstock / TAM99PH

It is stated that based on studies conducted of individual omicron mutations, which include their cocktail of regen-cov antibodies and those created by vaccination, there may be a decrease in neutralizing activity in this strain.

“As vaccines need to adapt to new strains, we probably need to constantly improve our treatment of monoclonal antibodies,” said Regeneron Pharmaceuticals Inc.

And Eli Lily, another U.S. pharmaceutical company that produces an anti-covid 19 drug based on monoclonal antibodies, confirmed to Reuters that it is currently working to understand the effectiveness of its therapies on the omicron strain.

The U.S. Food and Drug Administration announced today that it is evaluating the effectiveness of covid vaccines approved against homicron strains and that it expects to have more information in the coming weeks.

Follow us on our own Facebook i Instagram page, Twitter account and join ours Viber community.



Leave a Reply

Your email address will not be published. Required fields are marked *